Mint Med: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of Mint Med’s website, https://mintmed.com, FDA Establishment Identifier (FEI) 3044896930, in May 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products. As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.

1. 1

   “1. The compounded semaglutide and tirzepatide products displayed on your website identify “Mint Med” on the pictured label, suggesting Mint Med is the compounder of those drugs when in fact it is not.”

2. 2

   “1. Identifying the entities that produce the compounded drug products offered on your website;”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

mintmed.com returned a live storefront on 2026-08-09 titled "MintMed | Doctor-Backed Treatments for Wellness & Vitality", advertising "GLP-1 All Doses $159 per month" and "NO memberships!", publishing a Cincinnati phone number (1-513-826-6142) consistent with the Ohio address on the letter, and running a $25 referral offer with a working checkout — an operating seller. No brand names (Ozempic, Wegovy, Mounjaro, Zepbound) appeared in the homepage as fetched.

Almost every letter in this collection quotes something the seller wrote. This one quotes nothing, because there was nothing to quote — FDA's entire finding is that the vial in the product photograph had the storefront's name on it, and the storefront did not make the drug. That is worth sitting with, because it is the finding a shopper is least equipped to catch. Marketing copy can be read and doubted; a label in a product image reads as documentation. Under FDA's regulation, a name printed on a drug label without qualification is a representation that the named party is the sole manufacturer, so putting a brand on the vial answers the question "who made this" — and here it answered it incorrectly. The practical consequence is about traceability rather than danger: if the compounder's name is not on the label, then a buyer cannot look up the facility, cannot check whether it is a 503A pharmacy or a registered 503B outsourcing facility, and has no way to connect a bad batch to a source. FDA asked the company to name the producing entities, which is the same question a careful buyer would ask. Nothing in the letter concerns the drug's quality or contents. The site is trading today at $159 a month for all doses, a price shape that only makes sense when someone else is doing the compounding.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Mint Med failed to respond.